Effect of seizure timing on long-term survival in patients with brain tumor

2021 ◽  
Vol 117 ◽  
pp. 107566
Author(s):  
Suyash Singh ◽  
Anant Mehrotra ◽  
Soumen Kanjilal ◽  
Vimal K. Paliwal
Keyword(s):  
Brain Tumor ◽  
Term Survival ◽  
Long Term Survival

scholarly journals ACTR-18. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: AN UPDATE FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM

2016 ◽  
Vol 18 (suppl_6) ◽  
pp. vi5-vi5
Author(s):  
Caroline Happold ◽  
Riccardo Soffietti ◽  
Christine Marosi ◽  
Jaap Reijneveld ◽  
Gabriele Schackert ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Molecular Genetic ◽  
Term Survival ◽  
Long Term Survival ◽  
The Brain

scholarly journals Glioblastoma with Both Oligodendroglioma and Primitive Neuroectodermal Tumor-Like Components in a Case with 9-Year Survival

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Ying-Tso Chen ◽  
Shu-Shong Hsu ◽  
Chi-Man Yip ◽  
Ping-Hong Lai ◽  
Huai-Pao Lee
Keyword(s):  
Brain Tumor ◽  
Primitive Neuroectodermal Tumor ◽  
Case Reports ◽  
Primary Brain Tumor ◽  
Neuroectodermal Tumor ◽  
Disease Course ◽  
Term Survival ◽  
Long Term Survival ◽  
Genetic Features

Introduction. Glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults, is characterized by extensive heterogeneity in its clinicopathological presentation. A primary brain tumor with both astrocytic differentiation and neuronal immunophenotype features is rare. Here, we report a long-term survival patient who presented this rare form of GBM in the disease course. Presentation of Case. A 23-year-old woman, presenting with rapidly progressive headache and right-side weakness, was diagnosed with brain tumor over the left basal ganglion. She underwent the first craniectomy for tumor removal, and histopathology revealed classic GBM. Tumor recurrence occurred 8 years later. Another gross total resection was performed and pathology revealed GBM with the oligodendroglioma component (GBM-O). Due to disease progression, she received debulking surgery the following year. The third pathology revealed glioblastoma with primitive neuroectodermal tumor-like component (GBM-PNET). Discussion. GBM-PNETs are collision tumors with both neuronal and glial components. They are rare, and a few case reports have suggested that these tumors are associated with favorable outcomes but a higher risk of cerebrospinal fluid dissemination. Conclusion. We report a patient who developed the distinct pathologic variants of classic GBM, GBM-O, and GBM-PNET, throughout the disease course. Young age, aggressive surgical resection, and pathologic and genetic features may have contributed to the long-term survival of the patient.

Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 2056-2056 ◽  
Author(s):  
Michael Weller ◽  
Guido Reifenberger ◽  
Emilie Le Rhun ◽  
Jennifer Leigh Clarke ◽  
Riccardo Soffietti ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Dna Methyltransferase ◽  
Methylation Status ◽  
Related Factors ◽  
Immunological Parameters ◽  
Term Survival ◽  
Long Term Survival ◽  
Large Patient ◽  
The Us

2056 Background: Glioblastoma represents the most aggressive primary brain tumor in adults, and less than 5% of patients survive 5 years from diagnosis. Factors influencing this long-term survival are poorly understood. Methods: In cooperation with the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium, more than 20 clinical sites in the US, Europe and Australia have registered patients with centrally confirmed glioblastoma who survived ≥ 5 years, collecting clinical data including therapy and quality of life-related factors, as well as biospecimens allowing to analyse molecular and immunological parameters. Results: At the cut-off of December 31, 2018, 392 patients were registered, of which 232 had glioblastoma confirmed by central pathology review; 59 dropped out due to histology other than glioblastoma. Glioblastomas were isocitrate dehydrogenase (IDH)-wildtype in 70.7% and had a positive O6-methylguanine DNA methyltransferase (MGMT) promotor methylation status in 75.9%. Median age at diagnosis was 52 years (range: 21-77 years). There was enrichment for patients with gross total resection. Further analyses are ongoing. Conclusions: In a comprehensive effort, the consortium funded by the US Brain Tumor Funders’ Collaborative characterizes factors modulating long-term survival in glioblastoma in a unique large patient cohort. Clinical trial information: NCT 03770468.

scholarly journals Long-term Survival in Stage IV Sigmoid Colon Cancer Initially Presenting as a Brain Tumor: Case Report

2011 ◽  
Vol 44 (1) ◽  
pp. 84-91
Author(s):  
Shintaro Nakajima ◽  
Katsuhito Suwa ◽  
Kazuo Kitagawa ◽  
Akihiko Fujita ◽  
Tetsuya Yamagata ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Brain Tumor ◽  
Case Report ◽  
Sigmoid Colon ◽  
Stage Iv ◽  
Sigmoid Colon Cancer ◽  
Term Survival ◽  
Long Term Survival

scholarly journals ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi5-vi6
Author(s):  
Caroline Happold ◽  
Jörg Felsberg ◽  
Jennifer Clarke ◽  
Riccardo Soffietti ◽  
Christine Marosi ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Molecular Genetic ◽  
Term Survival ◽  
Long Term Survival ◽  
First Results ◽  
The Brain

scholarly journals Functional mapping–guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival

2011 ◽  
Vol 114 (3) ◽  
pp. 566-573 ◽  
Author(s):  
Edward F. Chang ◽  
Aaron Clark ◽  
Justin S. Smith ◽  
Mei-Yin Polley ◽  
Susan M. Chang ◽  
...  
Keyword(s):  
Brain Tumor ◽  
High Risk ◽  
Functional Mapping ◽  
Low Grade ◽  
Brain Areas ◽  
Term Survival ◽  
Long Term Survival ◽  
Low Grade Gliomas ◽  
Eloquent Areas

Object Low-grade gliomas (LGGs) frequently infiltrate highly functional or “eloquent” brain areas. Given the lack of long-term survival data, the prognostic significance of eloquent brain tumor location and the role of functional mapping during resective surgery in presumed eloquent brain regions are unknown. Methods We performed a retrospective analysis of 281 cases involving adults who underwent resection of a supratentorial LGG at a brain tumor referral center. Preoperative MR images were evaluated blindly for involvement of eloquent brain areas, including the sensorimotor and language cortices, and specific subcortical structures. For high-risk tumors located in presumed eloquent brain areas, long-term survival estimates were evaluated for patients who underwent intraoperative functional mapping with electrocortical stimulation and for those who did not. Results One hundred and seventy-four patients (62%) had high-risk LGGs that were located in presumed eloquent areas. Adjusting for other known prognostic factors, patients with tumors in areas presumed to be eloquent had worse overall and progression-free survival (OS, hazard ratio [HR] 6.1, 95% CI 2.6–14.1; PFS, HR 1.9, 95% CI 1.2–2.9; Cox proportional hazards). Confirmation of tumor overlapping functional areas during intraoperative mapping was strongly associated with shorter survival (OS, HR 9.6, 95% CI 3.6–25.9). In contrast, when mapping revealed that tumor spared true eloquent areas, patients had significantly longer survival, nearly comparable to patients with tumors that clearly involved only noneloquent areas, as demonstrated by preoperative imaging (OS, HR 2.9, 95% CI 1.0–8.5). Conclusions Presumed eloquent location of LGGs is an important but modifiable risk factor predicting disease progression and death. Delineation of true functional and nonfunctional areas by intraoperative mapping in high-risk patients to maximize tumor resection can dramatically improve long-term survival.

Effect of seizure timing on long-term survival in patients with brain tumor

2020 ◽  
Vol 111 ◽  
pp. 107307
Author(s):  
Vibhangini S. Wasade ◽  
Tanuwong Viarasilpa ◽  
Indranil Balki ◽  
Gamaleldin Osman ◽  
Arya Gaddam ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Multi-layered core-sheath fiber membranes for controlled drug release in the local treatment of brain tumor

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Daewoo Han ◽  
Riccardo Serra ◽  
Noah Gorelick ◽  
Umailla Fatima ◽  
Charles G. Eberhart ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Release Kinetics ◽  
Local Treatment ◽  
Cytotoxic Agents ◽  
Term Survival ◽  
Long Term Survival ◽  
9L Gliosarcoma ◽  
Fiber Membranes

AbstractInterstitial chemotherapy plays a pivotal role in the treatment of glioblastoma multiforme (GBM), an aggressive form of primary brain cancer, by enhancing drug biodistribution to the tumor and avoiding systemic toxicities. The use of new polymer structures that extend the release of cytotoxic agents may therefore increase survival and prevent recurrence. A novel core-sheath fiber loaded with the drug carmustine (BCNU) was evaluated in an in vivo brain tumor model. Three-dimensional discs were formed from coaxially electrospun fiber membranes and in vitro BCNU release kinetics were measured. In vivo survival was assessed following implantation of discs made of compressed core-sheath fibers (NanoMesh) either concurrently with or five days after intracranial implantation of 9L gliosarcoma. Co-implantation of NanoMesh and 9L gliosarcoma resulted in statistically significant long-term survival (>150 days). Empty control NanoMesh confirmed the safety of these novel implants. Similarly, Day 5 studies showed significant median, overall, and long-term survival rates, suggesting optimal control of tumor growth, confirmed with histological and immunohistochemical analyses. Local chemotherapy by means of biodegradable NanoMesh implants is a new treatment paradigm for the treatment for brain tumors. Drug delivery with coaxial core-sheath structures benefits from high drug loading, controlled long-term release kinetics, and slow polymer degradation. This represents a promising evolution for the current treatment of GBM.

Sign in / Sign up

Export Citation Format

Share Document